Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Bill Or Drug Pricing Bill? House Members Makes Both Cases

Executive Summary

House passes bill reauthorizing FDA user fee programs via voice vote and makes many other policy changes, but in the process touts the bill's potential to push drug prices lower.

You may also be interested in...



On to PDUFA VII? Yes And No, Woodcock Says, With Sentiment Of Fatigue

The CDER director said the US agency is always thinking about the next iteration of the prescription drug user fee program, but added that it has not yet discussed specifics. 

Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.

Finally, Drug Pricing Consensus: There's No 'Silver Bullet' For This Werewolf

All sides have resorted to the mythological phrase throughout the debate, and industry can only hope that the phase of the moon changes soon.

Related Content

Topics

UsernamePublicRestriction

Register

PS121090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel